Audit: QRS - Palmitoyl Pentapeptide for Skin Rejuvenation

Audit conducted on 13/09/2026 12:51 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to ER lines 321–325, time cells to ER lines 341 and 380, benefits/risks to the ER tier headings, gates to ER lines 276–299, monitoring table to ER lines 410–416, cadence to ER line 406, qualitative items to ER lines 420–424.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established target value” carried verbatim into marker_1_target; “Firmness and hydration improve inconsistently” mirrors the ER Conclusion’s “improve inconsistently”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Caution/Monitor grades in caution_items match the ER verbatim; the four contraindications retain their time windows and “until the skin is intact” conditions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; Benefit- and Risk-Modifying Factors are not surfaced anywhere. The “Age considerations” time cell carries an assessment window, not a caution.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, author names, NCT identifiers or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Restrained, evidence-weighted register matching the ER, including the ER’s own displacement framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Concentrations, intervals and biomarker ranges are given concretely while remaining readable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are impersonal and descriptive throughout (“Application to the eyelid margin itself…”, “Judging a product before 12 weeks… is premature”).
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or directive constructions; all protocol content is stated as observed practice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “must” in the document voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Instrument names in the Monitoring table are glossed as in the ER (“Corneometry (skin hydration)”, “Transepidermal water loss (TEWL)”).
2.8	Information is presented in a concise and very compact manner	🟢	Gate items and tier lists are stripped to the key fact; the at-a-glance runs 55 words.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for first- and second-person pronouns.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to photograph, instrument and re-test at fixed intervals.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily application, a 12-week judgement point and annual blood markers are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Cutometry, corneometry and TEWL targets are well beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The Medium risk is opportunity cost (“Forgone Benefit From Displacing a Better-Evidenced Topical”), and the at-a-glance names the better-evidenced comparator.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route of administration is stated formally (“Leave-on serums or creams”, “applied before heavier occlusive moisturizer”); tier entries use the ER’s clinical headings (“Favorable Local Tolerability Relative to Retinoids”, “Eyelid and Periorbital Dermatitis From Periocular Application”).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte for byte (lines 443, 483, 529, 551, 566, 590, 613, 617–619, 621, 721).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Mechanical diff of span names against the template: every template span is present, with marker_#_* expanded to markers 1–7 and qualitative_item_# expanded to items 1–5. No extra or missing names.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three non-variable spans (website="evidence_review", website="audit", website="full_review") are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty; the High tiers carry explanatory text and are handled under 12.5 / 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard concentration”, “Frequency”, “Best time of day” and “Age considerations” are the ER’s own bold labels; all seven interaction labels are carried verbatim from ER lines 276–292.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Tier entries reuse the ER’s H4 headings, monitoring markers reuse the ER table’s biomarker names, and the two time-cell labels are lifted from the ER’s own wording inside the Time to effect bullet (“wrinkle differences”, “Instrumented smoothness”).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s ⚠️ and ⭕️ markers on two benefit headings were correctly stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Three protocol cells, three time cells, four gate items, seven interactions, seven markers and five qualitative items sit within the one-page budget.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preceding text is the template’s comment caption.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are repeated in the header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: palmitoyl_pentapeptide_skin_2026-0913-1025_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0913-1235.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Palmitoyl Pentapeptide for Skin Rejuvenation - Quick Reference Sheet”; no characters require entity encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Palmitoyl Pentapeptide for Skin Rejuvenation”, matching ER frontmatter line 8.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/13/2026”, correctly derived from 2026-0913-1235.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all three Conclusion paragraphs (ER lines 446–450): what it is, what the human evidence supports, the low hazard, and the displacement cost.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words, counted mechanically.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence: “carried into the skin on a fatty acid tail, sold in leave-on creams at a few parts per million”; “the treated side of a face showed fewer fine lines”; “Hydration and firmness readings improve inconsistently”; “there is little to fear. Nothing measurable enters the bloodstream”; “vitamin A creams have a far larger and better-replicated evidence base for the same goal”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “vitamin A creams” is used in place of “retinoids”, and “collagen fragment” in place of “matrikine”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, participant count or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	The ER’s 0.27 scale-point pooled difference and its p-value are omitted.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items come from the “Populations who should avoid Palmitoyl Pentapeptide” list at ER lines 294–299.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Four ER bullets, four QRS items, in the same order, with none added or dropped.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Four discrete <li> elements inside the stop_items span (lines 554–561).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The em-dash clause “— absolute contraindication” is stripped from item 1, and the ocular-irritant rationale after the semicolon is stripped from item 4; the leading “Anyone with / Anyone applying” is reduced to the bare condition.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 7 to 14 days”, “(trichloroacetic acid 35% or deeper)”, “until re-epithelialization is complete” and “until the skin is intact” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four such scenarios and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the bullets at ER lines 276–292.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Every ER bullet carrying a Caution or Monitor grade is present; the two bullets that state no interaction exists (“Supplement interactions”, “Supplements with additive effects on the same target”, ER lines 288–290) are correctly excluded from a caution gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven discrete <li> elements inside the caution_items span (lines 569–580).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to label plus grade; the ER’s mechanistic sentences and mitigation instructions (alternating nights, 30-minute separation, wet-on-wet layering) are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The retinoid and acid example lists, the “hydrocortisone 1%” threshold, the isotretinoin window “while on treatment and for one month after”, and the device list “(fractional laser, microneedling, radiofrequency)” are all retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names several such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER Therapeutic Protocol bullets at lines 321–325.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Concentration, frequency and timing — the ER’s own first three bullets and the only ones that specify what to apply, how often and when.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The 12-week wrinkle assessment, the 4-week earliest instrumented reading (ER line 380) and the extended 16–24 week window above age 60 (ER line 341).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Time 1 attaches to the sole Medium-tier benefit (fine lines and wrinkles), time 2 to the Low-tier instrumented endpoints, and time 3 to the age-modified window.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content; the values “12 weeks”, “4 weeks” and “16 to 24 weeks” all appear in the ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information (ER lines 341, 380), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All seven entries are the ER’s H4 benefit headings from lines 146–192.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 531–544 with the correct tier labels.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; the ER’s Magnitude paragraphs, trial descriptions and the ⚠️ Conflicted / ⭕️ Not Central markers are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	No benefit reaches High in the ER; the benefits_high span carries style="display: none" (line 531) and no empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven entries are the ER’s H4 risk headings from lines 216–258.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 592–607 with the correct tier labels.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; the ER’s Magnitude figures (1 of 10 subjects, score 0.10, 21,793 adults, 27.5%) and the industry-funding notes are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER heading’s “(Redness)” parenthetical is correctly stripped from the Low-tier irritation entry; no parentheses remain.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	No risk reaches High in the ER; the risks_high span carries style="display: none" (line 592) and no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER Monitoring Protocol & Defining Success table at lines 408–416.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER rows are present in ER order — wrinkle severity grade, corneometry, TEWL, cutometry R2, plasma vitamin C, HbA1c, 25-hydroxyvitamin D — with target ranges and rationales carried across intact.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 713–715 condense ER line 406: readings at 4 weeks, 12 weeks, then every 6 months; blood markers annually or sooner if a baseline value fell outside range.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from the “Qualitative markers worth tracking” list at ER lines 418–424.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER bullets are present verbatim and in ER order (QRS lines 724–742).

Issues 13/09/2026 12:51

Pass rate 100.00%. No issues found.

Issues 13/09/2026 12:45

1. 4.2 / 4.3 — Invented Time-to-Effect label: [time_3_label] (QRS line 513) reads “Above roughly 60”, a fragment lifted from the body of the ER bullet, instead of the ER’s own bold label “Age considerations” (ER line 341).
2. 1.3 — Concentration range hedge dropped: [action_1_value] (QRS line 450) states “3 to 8 parts per million” where the ER reads “roughly 3 to 8 parts per million” (ER line 321), presenting an approximate range as exact.

Fixes 13/09/2026 12:45

1. 4.2 / 4.3 — Time-to-Effect label restored to ER wording: [time_3_label] changed from “Above roughly 60” to the ER’s own bold label “Age considerations”; the dropped age threshold was carried into [time_3_sub], which now opens “Above roughly 60, the assessment window extends…”.
2. 1.3 — Concentration hedge restored: [action_1_value] changed from “3 to 8 parts per million” to “Roughly 3 to 8 parts per million”, matching the ER’s approximate range.

Issues 13/09/2026 12:41

1. 12.3 — Trailing qualifiers on benefit items: “Improved Skin Elasticity and Firmness — conflicted” (line 538) and “Accelerated Wound Healing and Post-Procedure Recovery — not central to skin rejuvenation” (line 543) append evidence-strength and scope qualifiers that the tier label already encodes.
2. 13.4 — Parenthetical preserved in risk item: “Application-Site Irritation, Stinging or Erythema (redness)” (line 600) keeps the parenthetical gloss that 13.4 requires to be stripped.

Fixes 13/09/2026 12:41

1. 12.3 — Trailing qualifiers on benefit items: Stripped “— conflicted” from “Improved Skin Elasticity and Firmness” and “— not central to skin rejuvenation” from “Accelerated Wound Healing and Post-Procedure Recovery” in [benefits_low] and [benefits_speculative].
2. 13.4 — Parenthetical preserved in risk item: Removed the “(redness)” gloss from “Application-Site Irritation, Stinging or Erythema” in [risks_low].